Home

Biotron Limited – Developing a new class of antiviral therapies

Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections. Importantly BIT225 inhibits HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.